On July 13, 2022 EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry with its Asian regional headquarters in Singapore and offices across Japan, China and other countries in the area, and Compai Pharma, an enterprising pharmaceutical company offering full-service commercialisation with offices in Singapore and Malaysia, reported a strategic partnership to expand service across the Asia Pacific region (Press release, EVERSANA, JUL 13, 2022, View Source [SID1234616608]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Together, EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners to support full market implementation and development for life science and pharmaceutical companies ready to expand into these markets.

"As the needs of clients and their patients continue to grow, so too do our capabilities to scale delivery on a global level," said Jim Lang, CEO, EVERSANA. "The Asia Pacific region is one of the fastest-growing pharmaceutical markets in the world and requires regional expertise to increase patient access. Together with Compai Pharma, we’re now able to drive greater value and services for our clients to support their evolving commercialisation needs."

Capabilities available through the partnership include consulting, market access, medical awareness, education and communication, pharmacovigilance, marketing & sales excellence, as well as distribution and additional services.

"I am deeply honoured and excited to enter this partnership with such an esteemed company as EVERSANA," said Tim Cushway, Founder and Director at Compai Pharma. "Our mission is to work closely with healthcare practitioners across APAC to ensure needed medications and devices are available for patients while also becoming a trusted partner to provide education and updates on the latest in clinical developments. This goal is highly synergistic with EVERSANA’s global ambition."

The partnership with Compai builds on EVERSANA’s continued global growth, including recent expansion across the European Union and the United Kingdom. Additionally in June 2021, EVERSANA announced the growth of its medical communications and integrated compliance services across 18 European countries and in 10 local languages.

On July 13, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, reported that the Company will report second quarter 2022 financial results on Thursday, July, 21, 2022, after market close (Press release, Cytori Therapeutics, JUL 13, 2022, View Source [SID1234616643]). Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available at ir.plustherapeutics.com/events.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s website under the ‘For Investor’ section. The webcast will be available on the Company’s website for 90 days following the live call.

On July 13, 2022 Triastek, Inc. ("Triastek") reported a collaboration with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to leverage the advantages of 3D printing technology to enable precisely targeted and programmed release of drugs in specific regions of the GI tract (Press release, Eli Lilly, JUL 13, 2022, View Source [SID1234616660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct an in-depth study of excipient properties and process parameters to maintain drug stability throughout the formulation development and 3D printing process, as well as during drug release. Secondly, identify a unique three-dimensional structure dosage form design, that will permit programmed release of drugs in specific parts of the intestine, with the goal of improving the bioavailability of orally administered drugs.

Triastek is a 3D printing technology platform company, and its pioneering MED technology has versatile applications in solid dosage forms development and manufacturing. With the facilitation of this collaboration by Lilly China Innovation & Partnerships, Triastek will work with Lilly to explore novel solutions to the oral delivery of drugs.

Triastek is committed to promoting the application of 3D printing technology in the pharmaceutical field. Triastek’s 1st and 2nd products (T19 and T20) have received IND clearance from the U.S. Food and Drug Administration (FDA). The company also holds 158 patent applications related to 3D printing of pharmaceuticals with comprehensive patent coverage in the world. Triastek has also established collaborations with a number of multinational pharmaceutical companies, as well as domestic pharmaceutical companies to provide technical solutions for the development of challenging formulations.

Dr. Senping Cheng, founder and CEO of Triastek, said: "the collaboration between Triastek and Lilly is a great example of applying MED technology for improving the oral delivery of drugs. We envision that the MED technology of Triastek can be used to solve the challenges in formulations leading to the development of clinically valuable products for our global partners."

On July 13, 2022 DNAnexus, Inc., a leading provider of cloud-based biomedical data analysis software serving the life sciences community, and Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported a collaboration aimed at accelerating research and reducing the time to design, validate, and commercialize new, high-quality, next-generation sequencing (NGS)-based diagnostic tests (Press release, Twist Bioscience, JUL 13, 2022, View Source [SID1234616644]). As part of the collaboration, Twist customers are able to use the integrated DNAnexus platform with Twist’s NGS Methylation Detection System and Unique Molecular Identifier (UMI) Adapter System to simplify data analysis after sequencing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Twist NGS Methylation Detection System provides robust sample preparation and target enrichment solutions for identifying methylated regions in the human genome. Rare diseases, cancer, and other disorders can be identified by unique methylation patterns within samples. The NGS Methylation Detection System uses highly sensitive hybridization capture-based technology that can be integrated into diagnostic tests. This workflow can also be used to better characterize and understand the genetic mechanisms linked to specific conditions including cancer, neurodegeneration, and rare diseases. The Twist UMI Adapter System detects low-frequency variants in low-input sample sources such as cell-free DNA (cfDNA) and can be used to enable cancer research. The DNAnexus platform allows users to easily explore and analyze complex datasets in a single, scalable, cloud-based environment.

"This collaboration with DNAnexus is another example of our ongoing commitment to providing our customers with the tools they need for complete, customized, end-to-end workflows," said Emily M. Leproust, PhD, CEO and co-founder of Twist Bioscience. "Our customers can now access industry-leading computational infrastructure platforms to support their bioinformatics needs and reduce their data analysis timeline after performing a sequencing run with our NGS Methylation Detection and UMI Adapter Systems."

Today, DNAnexus has more than 12,000 users across 48 countries and works with the largest and most innovative pharmaceutical companies, diagnostic laboratories, and academic medical centers around the world, along with the UK Biobank and the FDA. The platform provides a comprehensive cloud environment that supports the entire diagnostic development and production cycle from R&D through to deployment of the validated test. The environment was designed to meet the most rigorous standards for quality, security, privacy, and safety.

"Twist’s proprietary synthetic DNA tools continue to be used to advance research and precision medicine and to change the way diagnostics are developed," said John Ellithorpe, PhD, President of DNAnexus. "With the integrated DNAnexus platform, Twist customers can now reduce the complex data analysis bottleneck, which we believe will offer significant time savings and cost advantages."

On July 13, 2022 miR Scientific, LLC reported the miR Sentinel Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets (Press release, miR Scientific, JUL 13, 2022, View Source [SID1234616661]). miR Sentinel is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The results of a recent clinical study performed at multiple sites within the US and Puerto Rico were presented at the 2022 American Urological Association’s Annual Meeting. In the study cohort of ~1100 men, the miR Sentinel Test was shown to identify molecular evidence of prostate cancer in at-risk men with 98.5% sensitivity and distinguish clinically non-significant (nominally No Pathological Evidence of Prostate Cancer and Grade Group 1), from clinically significant prostate cancer (nominally Grade Groups 2-5) with a prognostic sensitivity of 83% 2.

"We believe that the miR Sentinel Test offers patients and providers a non-invasive means of accurately assessing a man’s prostate cancer risk, which could potentially reduce unnecessary biopsies and biopsy-related complications in men with low-risk of clinically significant prostate cancer, while prioritizing diagnostic and treatment resources to those men that potentially harbor clinically significant prostate cancer," said Sam Salman, Chairman and CEO of miR Scientific. "This aligns with miR Scientific’s vision to revolutionize prostate cancer disease management by improving accessibility and accuracy of the tools used to assess each man’s personal risk of aggressive disease."

In a subset analysis of men from this cohort where the findings of TRUS and MRI-guided biopsies disagreed on the presence of prostate cancer, the miR Sentinel Test was able to correctly identify 99% (71/72) of men found positive by either biopsy type while identifying all but 4 of 234 cases where prostate cancer was found by either TRUS or MRI resulting in a false negative rate of 1.7%. Additionally, 87% of men with PSA levels <3 found to have pathologic grade group 2 through 5 upon biopsy were identified by the miR Sentinel Test as having molecular evidence of intermediate or high risk of aggressive disease2. These findings suggest that the miR Sentinel Test may represent a significant improvement over the current standards of care and other tools being used to detect and classify prostate cancer.

"Accurate assessment of a man’s individual risk related to prostate cancer is one of the cornerstones of appropriate patient management. The miR Sentinel Test has the potential to provide a significant improvement over the current tools that are available to physicians," said Laurence Klotz, MD, FRCSC, CM, miR Scientific’s Chief Medical Officer, Professor of Surgery and Chair of Prostate Cancer Research, University of Toronto Sunnybrook. "The implementation of such an innovation into practice could have a dramatic impact on outcomes through appropriately guiding the need for further diagnostic workup in men with elevated risk of significant cancer and guiding treatment in those subsequently diagnosed."

The current version of the miR Sentinel Test represents a refined and clinically validated assessment developed for commercialization based on our comprehensive miR Sentinel PCC4 assay, which received FDA Breakthrough Device Designation in third quarter 2020 and the original three-test proof of concept, published in the Journal of Urology1 in September 2020.

Additional information on the miR Sentinel Prostate Cancer Test as well as information on how to access the test can be found by visiting miRSentinel.com or calling 855-55CALLMIR from the United States or +1 (855) 552-2556.